@article{article_12108, title={Lokal ileri evre skuamöz hücreli baş ve boyun kanserinde sisplatinle eş zamanlı kemoradyoterapi: Yan etki ve uygulanabilirlik analizi}, journal={Türk Onkoloji Dergisi}, volume={23}, pages={1–11}, year={2008}, author={Atasoy, Beste Melek and Dane, Faysal and Sarı, Murat and Akgün, Züleyha and Yumuk, Perran Fulden and Turhal, Nazım Serdar and Abacıoğlu, Ufuk and Şengöz, Meriç}, keywords={Baş ve boyun kanseri, eş zamanl›, kemoradyoterapi, sisplatin, skuamöz hücreli kanser, yan etki}, abstract={OBJECTIVES In this study, we assessed the side effects and the factors related to patients, disease and, treatment that might change the decision for concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer. METHODS A total of 65 patients (49 primary; 16 postoperative) who received curative radiotherapy (median 70 Gy) with conventional fractionation schedule were enrolled into the study. Concomitant cisplatin were administered either 60-80 mg/m2 every 3 weeks (n=57) or 40 mg/m2 weekly (n=8). RESULTS Concurrent chemotherapy was completed in 46.1% patients. Premature chemotherapy termination was done due to grade 3 adverse event (41.6%), patients’ refusal (19.4%) or physician decision (33.3%). Initial Karnofsky Performance Status (KPS) significantly predicted concurrent chemotherapy completeness (KPS ≥90, 63.8% vs KPS}, number={1}, publisher={TÜRK RADYASYON ONKOLOJİSİ DERNEĞİ}